Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 3/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | PRNP | P04156 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319415 | 0.83 | BACE1 (0.58) | BACE1GRM2ADORA3ADORA2AADORA1 | |
| SCHEMBL23795928 | 0.81 | BACE1 (0.41) | BACE1GRM2ACHE | |
| SCHEMBL5475850 | 0.81 | PTGES (0.44) | GRM2PTGESRXFP1PRNP | |
| SCHEMBL1599588 | 0.81 | APP (0.41) | BACE1ADORA2AADORA1DHFRACHE | |
| SCHEMBL14546441 | 0.77 | ALDH1A1 (0.43) | BACE1GRM2DHFRRXFP1 | |
| SCHEMBL22405969 | 0.75 | ADORA2A (0.46) | BACE1ADORA2AADORA1DHFRACHE | |
| SCHEMBL4261753 | 0.75 | AURKA (0.46) | BACE1GRM2ADORA3ADORA2AADORA2B | |
| SCHEMBL438920 | 0.74 | ACHE (0.70) | PTGESADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL18197830 | 0.73 | BACE1 (0.50) | BACE1ACHE | |
| SCHEMBL4264929 | 0.73 | BACE1 (0.51) | BACE1GRM2ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1845081-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048258-A1 | Amide Compound | DLAT, DGAT1, DGAT2 | BACE1 3142/4885GRM2 308/4885PTGES 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.